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Dopamine replacement therapy in the form of levodopa results in a significant proportion
of patients with Parkinson’s disease developing debilitating dyskinesia. This significantly
complicates further treatment and negatively impacts patient quality of life. A greater under-
standing of the neurobiological mechanisms underlying levodopa-induced dyskinesia (LID)
is therefore crucial to develop new treatments to prevent or mitigate LID. Such investiga-
tions in humans are largely confined to assessment of neurochemical and cerebrovascular
blood flow changes using positron emission tomography and functional magnetic reso-
nance imaging. However, recent evidence suggests that LID is associated with specific
morphological changes in the frontal cortex and midbrain, detectable by structural MRI and
voxel-based morphometry. Current human neuroimaging methods however lack sufficient
resolution to reveal the biological mechanism driving these morphological changes at the
cellular level. In contrast, there is a wealth of literature from well-established rodent mod-
els of LID documenting detailed post-mortem cellular and molecular measurements. The
combination therefore of advanced neuroimaging methods and rodent LID models offers
an exciting opportunity to bridge these currently disparate areas of research. To highlight
this opportunity, in this mini-review, we provide an overview of the current clinical evidence
for morphological changes in the brain associated with LID and identify potential cellular
mechanisms as suggested from human and animal studies. We then suggest a framework
for combining small animal MRI imaging with rodent models of LID, which may provide
important mechanistic insights into the neurobiology of LID.
Keywords: levodopa, magnetic resonance imaging,T1 relaxation, voxel-based morphometry, plasticity, prefrontal
cortex
INTRODUCTION
Parkinson’s disease (PD) is a multi-system neurodegenerative dis-
order that affects 1 in 100 people aged over 60 in the United
Kingdom. The disease is characterized pathologically by the pro-
gressive degeneration of nigrostriatal dopamine (DA) containing
neurons in the substantia nigra (1) and the accumulation of phos-
phorylated α-synuclein in Lewy bodies, ascending from the brain
stem to the higher area association cortices as the disease pro-
gresses (2). The subsequent depletion of DA in the caudate and
putamen of PD patients manifests itself as the classical triad of PD
motor symptoms, akinesia, resting tremor, and rigidity/postural
instability.
Some 44 years since its first use in the clinic (3), the first-
line treatment for many PD patients to alleviate their motor
symptoms remains pharmacological DA replacement with the
DA precursor levodopa (l-DOPA) (4). Although most patients
respond positively to l-DOPA treatment, after ~4–6 years of l-
DOPA therapy, a significant proportion of patients (~40%) exhibit
a decline in the therapeutic efficacy of l-DOPA and develop
debilitating dyskinesias (5). This phenomenon, termed levodopa-
induced dyskinesia (LID), is characterized by involuntary dystonic
and/or choreic movements of the trunk, limbs, and face, most
commonly when the plasma concentration of DA is high (“peak
dose” dyskinesia) (5). The expression of LID severely limits the
long-term clinical utility of l-DOPA in this sub-set of PD patients
and thus significantly impacts on patient quality of life. As such,
strategies to mitigate or prevent LID onset are the subject of intense
research efforts to address this serious unmet medical need. In the
clinic, these efforts are currently centered on modifying the timing,
formulation, and mode of administration for l-DOPA. In partic-
ular, emphasis is placed on delaying l-DOPA treatment where
possible by use of direct-acting DA receptor agonists (6) and if
not possible, using continuous intestinal l-DOPA infusion rather
than intermittent l-DOPA injections (7). Both approaches have
met with some success in reducing the incidence and severity of
LID. At the pre-clinical level, significant effort is being directed
toward understanding the role of other neurotransmitter systems
in LID, particularly the role of glutamate and serotonin, as well
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as the underlying molecular signaling pathways involved (8–10).
Despite these efforts, the neural mechanisms underlying LID in PD
remain obscure and the underlying neural correlates are not well
understood. This presents a significant barrier to development of
novel treatments (11).
In this article, we therefore examine current clinical evidence
that suggests neuroanatomical changes in the brain are associ-
ated with LID, and the caveats associated with this. Second, we
identify potential post-mortem cellular mechanisms as suggested
from human and animal studies, which may explain these abnor-
malities. Thirdly, we outline the framework for combining small
animal imaging with rodent models of LID, which may provide
important mechanistic insights into the neurobiology of LID.
NEURAL CORRELATES OF LEVODOPA-INDUCED DYSKINESIA:
functional MRI STUDIES
Research efforts to unravel the neural correlates of LID in the clinic
and in relevant animal models of LID are critical to address the
gaps in our knowledge of LID pathogenesis (12, 13). A fruitful
and translational strategy that can bridge clinical and pre-clinical
studies to achieve this is the application of neuroimaging tools
to both human patients and relevant animal models. In particu-
lar, the latter can provide a mechanistic framework to underpin
neuroimaging observations in patients.
To date, such investigations have typically focused on the use
of functional magnetic resonance imaging (fMRI) and positron
emission tomography (PET). These studies have identified changes
in brain network activity, metabolism and molecular changes
related to LID onset and severity, as described elsewhere (14–17).
In brief, it is clear from these studies that LID is associated with
bi-directionally altered neuronal firing patterns between the basal
ganglia and the neocortex, the net result of which is dis-inhibition
of thalamo-cortical neurons, leading to over-activation of frontal
cortical areas, particularly in the motor, pre-motor, and prefrontal
cortices. These data have been confirmed in PD patients with LID
using PET (14, 18), transcranial magnetic stimulation [TMS; Ref.
(19)], task-based and resting state fMRI (17, 20, 21).
NEUROANATOMICAL CORRELATES OF LEVODOPA-INDUCED
DYSKINESIA: STRUCTURAL MRI STUDIES
Functional magnetic resonance imaging studies have revealed sev-
eral important insights into LID pathophysiology. However, it is
also true that human neuroimaging studies consistently demon-
strate a linear relationship between the functional activity of the
brain, assessed by fMRI and the shape, volume, or thickness of
brain gray matter (22–24). These findings hold true for rodents as
well (25, 26). This structure–function relationship is most likely
driven by neuroanatomical remodeling at the cellular, synaptic
(neuronal dendrite), or vascular level as a consequence of altered
brain functional or metabolic activity (23, 27, 28). In other words,
changes in brain function usually lead to or are concurrent with
changes in the structure of the brain. Taking this into considera-
tion, it is perhaps surprising that the use of structural MRI (sMRI)
to probe whether there are neuroanatomical differences between
patients with LID and those who are not dyskinetic has not been
widely investigated.
In a recent study, the first of its kind to address this issue,
Cerasa et al. (29) utilized optimized voxel-based morphometry
(VBM) to analyze T1-weighted MR images from PD patients
with LID (n= 36), non-dyskinetic PD patients (n= 36), and age-
and sex-matched controls (n= 32). Compared to healthy con-
trols, both dyskinetic and non-dyskinetic PD patients showed
no significant differences in gray matter volume (GMV), some-
what consistent with other VBM findings in PD patients of a
similar age and disease duration, although the sample size was
small (29). However, when comparing dyskinetic versus non-
dyskinetic PD patients directly, a significant increase in GMV was
observed in the bilateral inferior frontal gyrus of the dyskinetic
patients (29). This increase was negatively correlated to age at
onset, such that the greatest increases in inferior frontal gyrus
GMV were in LID expressing PD patients with younger age of
onset (29). These data suggest a hypothesis that aberrant striato-
frontal and/or thalamo-cortical neural plasticity associated with
LID consequently leads to morphological remodeling of the pre-
frontal cortex (29), findings which have sparked an interesting
debate (30, 31).
The normalization and smoothing processes inherent to the
VBM pipeline may however lead to reduced sensitivity in assess-
ing cortical pathology, since individual sulci and gyri cannot be
accurately anatomically resolved (32, 33). As such, VBM therefore
provides a mixed measure of gray matter reflecting two compo-
nents, cortical surface area and cortical thickness. A direct measure
of cortical thickness therefore represents a topographical measure-
ment that might provide a more sensitive indicator of the integrity
of the cytoarchitecture in the cortex (32, 33).
To address this, Cerasa et al. (34) used surface-based investiga-
tion of cortical thickness in PD patients with LID (n= 29), without
LID (n= 30), and age- and sex-matched controls (n= 24). This
analysis revealed a pronounced increase in the thickness of the
right inferior frontal sulcus in the dyskinetic, as compared to non-
dyskinetic patients (34). These data support their original VBM
findings (29) and delineate with greater precision the anatom-
ical abnormalities characterizing dyskinetic PD patients (34). A
third study combining VBM and cortical thickness measurements
in PD patients with LID (n= 33) or without LID (n= 33), strat-
ified by their PD age-of-onset (< or >50 years of age), compared
to age- and sex-matched healthy controls (n= 40) reveals fur-
ther insights (35). Independent of the age of PD onset, dyskinetic
patients were characterized by increased GMV and thickness in the
inferior frontal cortex (35). Interestingly, early-onset PD patients
with dyskinesia also demonstrated increased GMV in the substan-
tia nigra and the red nucleus when compared to non-dyskinetic
patients (35). In contrast, late-onset PD patients with dyskine-
sia were characterized by GMV increases in the supplementary
motor area (SMA) only (35). Taken together, these data support
the previous observations of anatomical abnormalities associated
more generally with LID in the prefrontal cortex. Moreover, they
demonstrate that different spatial patterns of brain abnormali-
ties occur in patients with LID according to their age of PD
onset. In particular, nigral pathology may be important in early-
onset patients and in contrast, cortical pathology in late-onset
patients (35).
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LEVODOPA, GRAY MATTER, AND MAGNETIC RESONANCE
IMAGING SIGNAL
When interpreting VBM results, it is important to eliminate arti-
ficial causes for differences between processed images that do not
originate from genuine biological differences. In particular, MR
image contrast between tissue classes on T1-weighted MR images
is inversely proportional to the T1 relaxation time. Cerebrospinal
fluid (CSF) is dark, reflecting a long T1; whereas the much shorter
T1 of white matter renders it bright; and gray matter is inter-
mediate between these. When the brain is segmented into these
different tissue classes for volumetric analysis, VBM (and other
automated techniques, including cortical thickness) utilizes voxel
signal intensity profile (36). Each voxel has its own distinct inten-
sity profile and there is substantial overlap in the voxel intensity
histograms linked to gray and white matter. This renders precise
tissue class segmentation difficult, particularly in the presence of
partial volume effects, wherein a single voxel contains a mixture
of tissue types (37). This is particularly common when a voxel
spans distinct tissues, in cortical sulci (38). Such voxels are usually
excluded or allocated to a particular tissue type on a probabilis-
tic basis. As such, this segmentation process has the potential to
go awry in the presence of unrecognized changes in voxel inten-
sity profiles, leading to spurious volumetric findings (37). In other
words, a reported volume change might in fact be an artifact of
the signal acquisition and image analysis process (37).
This has recently been advanced as a biophysical explanation
for the effects of lithium, a mood stabilizer, to apparently increase
GMV (37). Whilst this notion is debated (39–41) and has yet to be
explored in detail, it is certainly important and warrants attention
(40, 41).
Interestingly, l-DOPA is associated with shortening of T1 (and
T2) relaxation time in vitro, although this may be influenced by
the presence of iron (42). This raises the possibility that changes
in T1 in the human brain after l-DOPA administration may lead
to an adjustment in the number of voxels that are attributed to
gray matter. These would then be detected by VBM analysis as an
apparent increase in GMV. Consistent with this hypothesis, VBM
analysis reports an increase in voxels attributed to gray matter
in the substantia nigra, ventral tegmental area, and subthalamic
nucleus following acute l-DOPA administration in healthy volun-
teers (43). Unfortunately, this study did not include quantitative T1
parametric mapping to assess the impact of l-DOPA on T1 in vivo.
These findings following a single administration of l-DOPA to
healthy people may lead to the suggestion differences in anatom-
ical MRI data acquired from dyskinetic and non-dyskinetic PD
patients (29, 34, 35), are driven by simple changes in signal inten-
sity (grounded in increases in proton T1), which may be misin-
terpreted as a volume increase in the gray matter. Importantly,
therefore, the gray matter volume increases reported in dyskinetic
PD patients were detected only in dyskinetic patients compared
to non-dyskinetic patients. All of these patients were receiving
l-DOPA therapy at the time of scanning, with no significant
difference in the duration of l-DOPA treatment (29, 34, 35).
Taken together, this does not support a general influence of
l-DOPA on the MRI signal driving the observed results, since
such an effect would be predicted to be present in both l-DOPA
treated patient groups. The fact that the anatomical abnormalities
are only present in the dyskinetic group strongly suggests these
are inherently linked to the pathogenesis of LID. We note however
that Lewis and colleagues report an accumulation of iron in the red
nucleus of patients with l-DOPA-induced dyskinesia (44). Iron is
paramagnetic and causes a reduction in both T2 and T1 relaxation
time in brain regions where brain iron is deposited in the form
of ferritin and hemosiderin (45). As such, whilst there is no evi-
dence currently to suggest that neuroanatomical brain changes in
dyskinetic PD patients are the result of an MR image artifact, quan-
titative T1 and T2 mapping may be recommended for future MRI
studies in dyskinetic and non-dyskinetic patients. This would help
to more accurately probe the exact origins of MRI signal changes
in these groups. Alternatively, controlled animal studies may be
important as MRI volume changes can be verified post-mortem, as
we have shown previously (28, 39, 46, 47), and discussed later in
this article.
WHAT IS THE MECHANISM UNDERLYING
NEUROANATOMICAL CHANGE IN GRAY MATTER
FOLLOWING CHRONIC L-DOPA TREATMENT?
Assuming that dyskinesia following l-DOPA treatment is asso-
ciated with physical neuroanatomical changes in the brain, the
next obvious issue is the identification of the underlying biolog-
ical mechanism. However, neuroimaging measures are difficult
to relate unambiguously to underlying biology (23). In partic-
ular, human neuroimaging studies cannot establish if the mor-
phological abnormalities in the prefrontal cortex of dyskinetic
PD patients are a cause or consequence of dyskinesia, following
chronic l-DOPA treatment (29). One very plausible hypothesis
is that these morphological changes reflect heightened activity
within the neuronal circuitry implicated in LID pathogenesis (29).
In other words, the detected pattern of brain abnormalities reflects
altered neurobiological mechanisms central to the pathogenesis of
LID. This hypothesis is supported by observations in hyperkinetic
movement disorders such as dystonia. Indeed, dystonia is associ-
ated with exaggerated increases in GMV of specific brain regions
involved in somatosensory processing, such as the basal ganglia,
prefrontal cortex, and somatosensory cortex (35, 48). Further-
more, it is suggested that l-DOPA, when applied in a pulsatile
and non-physiological manner may perturb the normal physio-
logical mechanisms that mediate motor control (49). This process
may lead to aberrant increases in synaptic plasticity, remodeling
of neuronal synapses, and changes in the functional connectivity
signature of brain activity within circuits responsible for motor
control. At the cellular level, this is likely to manifest as increases
in the size of neuronal dendritic arbors (50, 51). This phenome-
non termed, “l-DOPA-maladaptive plasticity” may be critical to
LID pathogenesis (29). Interestingly, this has also been suggested
as an explanation for the incidence of tardive dyskinesia following
chronic treatment with first generation antipsychotic drugs (52).
Evidence from recent studies using electroencephalography
(EEG) and fMRI support this hypothesis. These reveal that brain
activity and functional connectivity, defined as spontaneous, tem-
porally coupled blood oxygen level dependent (BOLD) oscil-
lations, is decreased in PD patients within the motor circuit
in the cortex that receives dopaminergic innervation including
the frontal, somatosensory, motor, and SMA (20, 21, 53–55).
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Furthermore, these studies confirm that acute and chronic
l-DOPA treatment restores this lost connectivity with motor net-
works and increases neural activity in these brain regions (20,
21, 53–55). In an acute setting, this may explain the therapeu-
tic effects of l-DOPA. However, with chronic treatment and the
continued degeneration of the dopaminergic system, this could
result in l-DOPA maladaptive plasticity leading to changes in
neural arborization, and subsequently the observed neuroanatom-
ical increases in the cortex of dyskinetic PD patients. Alternatively,
such neuroanatomical enlargements could equally reflect a struc-
tural long-term consequence of the altered neural plasticity in
these specific regions.
In reality however, MR phenomena are likely to be driven by
several cellular processes; acting potentially in parallel in multiple
cell types within the brain (23). Neuronal changes in gray mat-
ter as a cause or consequence of chronic l-DOPA treatment may
include neurogenesis, synaptogenesis, and changes in neuronal
morphology as discussed above. However, extra-neuronal changes
may equally be responsible and these could include increases in
glial cell size, morphology, number and additionally, angiogene-
sis. Indeed, the vasculature accounts for about 5% of gray matter
(56). Glial cells (astrocytes, microglia, and oligodendrocytes) are
believed to outnumber neurons by ~6 to 1, with varying ratios in
different brain regions. Any of these cellular changes may influence
MRI signals. Importantly, variations in neuronal, glial, and synap-
tic density may affect modalities sensitive to the proportion of
cellular material versus extracellular space in a voxel, such as pro-
ton density imaging or relaxometry. Such features would therefore
influence commonly used methods to assess gray matter change
including VBM and cortical thickness that rely on image intensity
boundaries in T1-weighted images (54).
Addressing this issue is problematic. In patients, one fruit-
ful approach may be to conduct multi-modal neuroimaging in
dyskinetic and non-dyskinetic PD patients to study the interrela-
tionships between brain function, metabolism, and structure. This
could include, but is not limited to, collection of resting state fMRI,
sMRI and quantitative T1 mapping in the same session. Similarly,
angiogenesis could be detected by techniques such as contrast-
enhanced imaging of blood volume or perfusion imaging of
cerebral blood flow (CBF). Recent advances in simultaneous PET–
MRI, the feasibility of which has been demonstrated in rodents
(57) and humans (58, 59) make this even more tractable and could
provide unparalleled insights into the pathophysiology of LID.
Ultimately, post-mortem histological studies are required in
order to make direct links between imaging measures and under-
lying mechanisms. For example, recent studies in our laboratory
have established that neuroanatomical changes, including a reduc-
tion in the volume of the anterior cingulate cortex due to chronic
antipsychotic drug treatment are not due to the loss of neurons or
astrocytes (28). Similarly, in a very elegant study, mice subjected
to different forms of maze training displayed volume increases in
either the hippocampus (spatial maze) or striatum (cued maze),
reflecting the distinct brain systems involved in these tasks (27).
These MRI-derived measures of growth correlated with growth
associated protein-43 (GAP-43) staining post-mortem, a marker
for axonal growth cones, but not measures of neuronal size or
number (27). These data suggest the observed MRI volume change
reflected remodeling of neuronal processes, rather than neuroge-
nesis (27). These data highlight the need to study relevant animal
models to help unravel the neuroanatomical correlates of LID
observed on MRI in patients.
ANIMAL MODELS OF LID
Levodopa-induced dyskinesia can be modeled pre-clinically by
recapitulating the conditions required for its development in
humans, namely degeneration of the nigrostriatal tract fol-
lowed by chronic exposure to l-DOPA. The primary dopamin-
ergic cell loss models used for evaluation of dyskinesia are the
6-hydroxydopamine (6-OHDA) lesioned hemi-parkinsonian rat
and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
treated non-human primate (NHP). Repeated exposure of these
denervated animals over several weeks to daily treatment with
l-DOPA combined with a peripheral DOPA decarboxylase
inhibitor such as benserazide or carbidopa, leads to development
of abnormal involuntary movements (AIMs), which is consid-
ered an experimental proxy for human LID (13, 60–62). This can
be scored according to a variety of ratings scales (63, 64). In the
6-OHDA-lesioned rat, AIMs manifest unilaterally as axial (twist-
ing of the head, neck, and trunk), limb (repetitive or dystonic
movements involving the forepaw and/or limb), and orolingual
(vacuous chewing, tongue protrusion) phenomena on the side of
the body contralateral to the lesion (60). In MPTP-treated NHPs,
LID is bilaterally expressed and manifests as choreic and dystonic
movements of the limbs, especially the lower limbs, and flicking
of the fingers, trunk dystonias, and repetitive tongue protrusion
(65). The MPTP–NHP model more accurately reflects the human
expression of dyskinesia, but ethical and practical considerations
mean that the 6-OHDA-lesioned rat model is a very valuable tool
for pre-clinical research. Importantly, the mechanisms underly-
ing the development of LID and AIMs appear to be common to
both (13). Extensive research in both rat and NHP LID models,
including studies to assess the potential of new anti-dyskinetic
drug strategies, has identified a plethora of candidate mechanisms
in specific brain regions, which may underlie the pathogenesis of
LID (5, 66). Both striatal and extra-striatal systems are implicated,
as described in brief below.
STRIATAL MECHANISMS UNDERLYING LID
The role of DA in the striatum is to alter the response of medium
spiny neurons (MSNs) in both the direct and indirect pathways
to excitatory input from the corticostriatal pathway. The classi-
cal model of LID suggests the presence of high concentrations of
exogenous DA (derived from l-DOPA) causes hyperactivation of
the direct pathway (striatonigral) MSNs, which increases thala-
mocortical feedback and produces exaggerated motor function.
Dyskinesia is therefore believed to primarily involve chronic over-
activation of striatonigral MSNs (67, 68) and there is a wealth of
evidence for a particular role of dopamine D1 receptors (D1R) in
the development of LID in both patients and pre-clinical mod-
els (69–72). In reality the mechanisms involved are likely to be
considerably more complex (73) and a role for the indirect path-
way cannot be ruled out, especially as both D1R and dopamine
D2 receptor (D2R) agonists can provoke dyskinesia in primed
monkeys (74).
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The striatonigral GABAergic projection is a point of conver-
gence for, and is therefore modulated by, multiple neurotransmit-
ter systems that may be pathologically altered in dyskinetic PD
patients. The major input to the BG involves release of glutamate
from corticostriatal neurones, and together with DA and the mod-
ulatory activity of other neurotransmitters such as serotonin (5-
HT), this determines the activity of the output nuclei: the globus
pallidus internus (GPi) and substantia nigra pars reticulata (SNr).
There is evidence from animal models that this corticostriatal glu-
tamate release is increased in LID (75, 76), alongside alterations
in expression (69, 77–80), phosphorylation (81–83), and distribu-
tion (84, 85) of glutamate receptors, including NR1/NR2B NMDA
receptors and metabotropic glutamate receptor 5 (mGlu5), that
facilitate increased signaling across this synapse. Morphological
alterations indicative of increased glutamatergic transmission are
also present (86). This is borne out in human LID, where abnor-
mal glutamatergic transmission has been described in the caudate,
putamen, and motor cortex (87), alongside increased putaminal
expression of NR1/NR2B NMDA receptors (88) and mGlu5 recep-
tors (80). Activation of extrasynaptic NR2B-containing NMDA
receptors has particularly been implicated in the development of
LID (84).
The effect of this abnormal glutamatergic transmission may
be compounded by the consequences of dysregulated release of
DA from serotonergic terminals within the striatum (89), lead-
ing to abnormal activation of DA receptors. These receptors are
expressed on striatonigral MSNs as well as in cortical dopamin-
ergic systems, which have also been implicated in the pathophys-
iology of dyskinesia (90). There are some reports of altered D1R
expression or trafficking in LID (70, 91), but evidence suggests that
the key mechanism in dyskinesia is increased functional sensitivity
of these receptors (92, 93).
Whatever the exact mechanism behind increased D1R sig-
naling, stimulation of these receptors causes activation of the
cyclic AMP (cAMP)/protein kinase A (PKA)/DARPP-32 (DA- and
cAMP-regulated phosphoprotein, 32 kDa)/protein phosphatase 1
(PP-1) pathway and the mitogen activated protein kinase (MAPK)
pathway, which culminates in phosphorylation of extracellular
signal related kinase (ERK1/2) (94). This results in DNA modifi-
cations (95, 96) and increased expression of transcription factors,
especially ∆FosB/FosB (97), which are indicative of long-term
cellular adaptations.
Both NMDA and mGlu5 receptors are known to closely inter-
act with D1R (81, 98) and with each other (99, 100), activat-
ing common downstream mediators such as PKA and ERK1/2
(101, 102). Therefore, the increased expression of these recep-
tors alongside enhanced D1R signaling will co-operate to augment
striatonigral signaling in LID. In addition, activation of D1R, in
combination with enhanced activation of NMDA receptors by glu-
tamate, leads to long-term potentiation-like phenomena. This may
explain the lack of depotentiation seen in the dyskinetic versus
non-dyskinetic denervated striatum (103), leading to an exag-
gerated response to normally irrelevant stimuli. The pathological
overactivation of the direct pathway leads to GABA bursting in
the SNr and GPi (71), thus disinhibiting thalamocortical feed-
back and leading to the hyperkinetic movements characteristic
of LID.
Striatal glutamatergic and dopaminergic transmission can
be modulated by several other neurotransmitters. For example,
increased serotonergic innervation of the striatum, along with
altered expression of several receptor subtypes (104, 105), has been
demonstrated in animal and human LID (106, 107). Importantly,
activation of serotonin 5-HT1A receptors has been shown to reduce
corticostriatal glutamate release (108,109),and also negatively reg-
ulates release of DA as a false neurotransmitter from serotonergic
terminals (110). Similarly the endocannabinoid system may play a
role in LID as activation of CB1 receptors has been shown to nega-
tively regulate corticostriatal glutamate release (111, 112) and also
reduce D1R-mediated responses (113–115). Consequently, mol-
ecules such as serotonin receptor 5-HT1A and 5-HT1B agonists
(116–120) and endocannabinoid receptor agonists (121–124) have
shown anti-dyskinetic efficacy.
EXTRA-STRIATAL MECHANISMS OF LID
As well as striatal alterations, there is also evidence from pharma-
cological studies suggesting that modulation of neurotransmission
elsewhere in the BG and in areas of the cortex may also contribute
to LID. Systemically active drugs could therefore produce anti-
dyskinetic effects through actions at more than one key synapse.
For example, antagonists of mGlu5, which are currently in clinical
trials as anti-dyskinetic agents (125, 126), may exert their effects
not only in the striatum but also in the subthalamic nucleus (127).
Targeting of 5-HT1A receptors in the subthalamic nucleus (128)
or primary motor cortex (129) also attenuates dyskinesia, as does
activation of 5-HT1B receptors (130, 131), which are not only
present in the striatum but also on GABAergic MSNs terminat-
ing in the SNr, where their activation can inhibit GABA release
(132). As well as the striatal actions already mentioned, another
potential mechanism to explain the efficacy of CB1 agonists is
potentiation of striatopallidal signaling via inhibition of GABA
reuptake (121), which would help to rebalance a hyperactivation
of striatonigral signaling. Opioid signaling, which is known to
be altered in LID (133–135), can modulate transmitter release at
several synapses within the BG, for example inhibition of stri-
atopallidal GABA release (136), and inhibition of glutamate and
GABA release into the SNr (137). Targeting several opioid receptor
subtypes has shown anti-dyskinetic efficacy (138–141), but their
role is complex and the effects of opioid-targeted approaches may
be dose-dependent (137).
FUTURE DIRECTIONS: A TRANSLATIONAL ROAD MAP TO
BRIDGE ANIMAL MECHANISTIC STUDIES WITH BRAIN
STRUCTURAL IMAGING TO IDENTIFY THE MORPHOLOGICAL
CORRELATES OF LID
These maladaptive plastic changes described above in the striatum
and extra-striatal regions may well underlie the morphological
changes associated with LID described in humans. Combining
well-validated rat and potentially, NHP, models of LID with
advanced non-invasive animal MR imaging methods therefore
offers an exciting opportunity to integrate currently disparate
areas of research and help explain the MR imaging phenomena
observed in dyskinetic patients (31) (Figure 1). This approach
is advantageous for three reasons. First, rodents and primates
allow one to assess the precise effects of drug treatment (in this
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FIGURE 1 | A translational methodological framework for the combination of rodent models of LID (or these could be non-human primates) with
multi-modal imaging, behavior and post-mortem cellular, or molecular analysis to elucidate the mechanisms underlying imaging phenomena
associated with levodopa dyskinesia observed in human Parkinson’s disease patients.
case, l-DOPA) on brain structure and function, disentangled
from potential confounding factors present in patient samples.
The proof-of-concept for this approach has been recently demon-
strated in our laboratory in characterizing the impact of chronic
antipsychotic drug treatment on rat brain morphometry (28, 39,
142). Second, the use of MRI/PET (clinically comparable technol-
ogy) permits the collection of parallel data read-outs in rodents,
primates, and humans, maximizing the possibility for translation
of basic findings to the clinic. Thirdly, and most importantly, as
we have seen in the preceding section, in animals one can mea-
sure neurochemical, biochemical, cellular, and molecular aspects
of brain structure and function in ways that are impossible in
human subjects. Thus neuroimaging and neuropathology may be
bridged to identify the biological mechanisms underlying MRI
phenomena.
A number of elegant functional imaging studies using small
animal micro-PET technology have begun to address this. Stud-
ies using PET in 6-OHDA lesioned rats chronically treated
with l-DOPA and displaying severe AIMs (the rodent LID
phenotype) display regional increases in CBF (measured using
[14C]-iodoantipyrine uptake), increases in regional cerebral glu-
cose utilization (rCGU; measured using [14C]-2-deoxyglucose
uptake) and DA release (measured using displacement of [11C]-
raclopride binding potential), consistent with similar findings
in PD patients (143–145). To date however, no studies have
assessed the impact of l-DOPA treatment on brain morphometry
or relaxation time in either rodent or primates, using advanced
structural MR imaging methods. This approach offers a unique
opportunity to answer a number of outstanding questions in
the emerging field of neuroanatomical alterations linked to l-
DOPA and LID pathogenesis. Multi-modal imaging approaches,
to study the interrelationships between brain anatomy [sMRI,
Diffusion Tensor Imaging (DTI)] metabolism [2-dexoyglucose,
1H-magnetic resonance spectroscopy (MRS)] and fMRI may be
of particular relevance. These imaging findings may then serve
as a “roadmap” to guide follow-up, region-specific post-mortem
investigation of the candidate mechanisms already identified in
these models, to help explain the imaging phenomena. Excitingly,
such studies are now underway in our laboratory.
Combining experimental models of LID with clinically compa-
rable technology may also be particularly important for the assess-
ment of novel anti-dyskinetic drugs, such as antagonists of mGlu5.
Indeed, as previously stated, the use of clinically comparable tech-
nology (MRI) to conduct parallel assessments in experimental
animals and humans is likely to accelerate translation of basic
findings to the clinic. Neuroimaging tools may therefore play a
critical role in future studies evaluating not only target engage-
ment, but also drug efficacy in models of LID, as evidenced by
recent studies using PET (143, 144, 146). No studies as yet have
employed MRI methods, but the potential for application of this
technology is apparent.
CONCLUSION
Recent human sMRI studies in PD patients with dyskinesia have
suggested the presence of neuroanatomical changes in specific
brain regions, particularly the frontal cortex, which may have
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relevance to the pathogenesis of dyskinesia. It is currently unclear
from these studies whether these abnormalities are the cause, or
consequence of dyskinesia. Furthermore, it is unclear if these
reflect genuine neuroanatomical changes in shape, thickness, or
volume of gray matter, or whether these can be explained by a
biophysical hypothesis relating to l-DOPA, as recently described
for the effects of lithium. Accepting this caveat and presuming
these changes to be genuine structural differences in gray mat-
ter, the biological mechanism underlying these changes remain
unknown, but may be rooted in maladaptive neuronal plastic-
ity, leading to remodeling of synapses and dendrites on neurons
and glia alike in the dyskinetic brain. However, a plethora of data
for candidate mechanisms underlying the pathophysiology of LID
exists from well-validated rodent and NHP pre-clinical models of
LID, which display excellent construct, face, and predictive validity
to human LID. The combination of these models with advanced,
multi-modal small animal MR imaging technology therefore offers
a unique opportunity to validate the presence of neuroanatom-
ical changes associated with LID. Furthermore, this will be an
important step to bridge neuroimaging and neuropathology to
link candidate mechanisms derived from animal models with neu-
roimaging phenomena in dyskinetic PD patients. Ultimately, this
will accelerate our understanding of LID pathogenesis and aid the
discovery and evaluation of novel anti-dyskinetic drug treatments.
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